Protein & Cell >

2020 , Vol. 11 >Issue 12: 915 - 920

DOI: https://doi.org/10.1007/s13238-020-00749-z

LETTER

Rewiring ERBB3 and ERK signaling confers resistance to FGFR1 inhibition in gastrointestinal cancer harbored an ERBB3-E928G mutation

  • Xiang Yang ,
  • Hongxiao Wang ,
  • Enjun Xie ,
  • Biyao Tang ,
  • Qingdian Mu ,
  • Zijun Song ,
  • Junyi Chen ,
  • Fudi Wang ,
  • Junxia Min
Expand
  • The First Affiliated Hospital, Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou 310058, China

Published date: 15 Dec 2020

Copyright

2020 The Author(s) 2020
Fold

Cite this article

Xiang Yang , Hongxiao Wang , Enjun Xie , Biyao Tang , Qingdian Mu , Zijun Song , Junyi Chen , Fudi Wang , Junxia Min . Rewiring ERBB3 and ERK signaling confers resistance to FGFR1 inhibition in gastrointestinal cancer harbored an ERBB3-E928G mutation[J]. Protein & Cell, 2020 , 11(12) : 915 -920 . DOI: 10.1007/s13238-020-00749-z

References

Publishing order | Descend order by publishing year | Descend order by cited within
1
Chen L, Mooso BA, Jathal MK, Madhav A, Johnson SD, van Spyk E, Mikhailova M, Zierenberg-Ripoll A, Xue L, Vinall RL (2011) Dual EGFR/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3. Clin Cancer Res 17 (19):6218–6228

DOI

2
Choi BK, Fan X, Deng H, Zhang N, An Z (2012) ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells. Cancer Med 1(1):28–38

DOI

3
Garrett JT, Sutton CR, Kurupi R, Bialucha CU, Ettenberg SA, Collins SD, Sheng Q, Wallweber J, Defazio-Eli L, Arteaga CL (2013) Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110alpha inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers. Cancer Res 73 (19):6013–6023

DOI

4
Huang X, Gao L, Wang S, McManaman JL, Thor AD, Yang X, Esteva FJ, Liu B (2010) Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin. Cancer Res 70:1204–1214

DOI

5
Jaiswal BS, Kljavin NM, Stawiski EW, Chan E, Parikh C, Durinck S, Chaudhuri S, Pujara K, Guillory J, Edgar KA (2013) Oncogenic ERBB3 mutations in human cancers. Cancer Cell 23 (5):603–617

DOI

6
Nguyen PT, Tsunematsu T, Yanagisawa S, Kudo Y, Miyauchi M, Kamata N, Takata T (2013) The FGFR1 inhibitor PD173074 induces mesenchymal–epithelial transition through the transcription factor AP-1. Br J Cancer 109(8):2248–2258

DOI

7
Ross JS, Fakih M, Ali SM, Elvin JA, Schrock AB, Suh J, Vergilio J-A, Ramkissoon S, Severson E, Daniel S (2018) Targeting HER2 in colorectal cancer: the landscape of amplification and short variant mutations in ERBB2 and ERBB3. Cancer 124 (7):1358–1373

DOI

8
Sithanandam G, Anderson LM (2008) The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther 15(7):413–448

DOI

9
Tanizaki J, Okamoto I, Sakai K, Nakagawa K (2011) Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification. British J Cancer 105:807–813

DOI

10
Verlingue L, Hollebecque A, Lacroix L, Postel-Vinay S, Varga A, El Dakdouki Y, Baldini C, Balheda R, Gazzah A, Michot J-M (2018) Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: entering the back door. Eur J Cancer 92:1–10

DOI

Options
Outlines

/

〈 〉